About the Company
LACQ is a blank check company formed for the purpose of effecting a merger or other business combination with a target company. Leisure is led by Lorne Weiland Daniel Silversand completed its Initial Public Offering in December 2017.
Employees
7915
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LACQ News
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, ...
Ensysce Biosciences, Inc. (ENSC)
As of 11:07 AM EDT. Market Open. SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company ...
Ensysce Biosciences Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe ...
Q4 2023 Ensysce Biosciences Inc Earnings Call
David Humphrey; Chief Financial Officer, Treasurer, Secretary; Ensysce Biosciences Inc Ram Selvaraju; Analyst; H.C. Wainwright & Company Inc Hunter Diamond; Analyst; Diamond Equity Research Brad ...
Ensysce Biosciences, Inc.: Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (" ...
Ensysce Biosciences, Inc.: Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pa ...
Ensysce Biosciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Ensysce Biosciences, Inc. (ENSCW)
Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to ...
Ensysce Biosciences Inc (ENSC)
SAN DIEGO - Ensysce Biosciences Inc. (NASDAQ:ENSC) has received guidance from the Food and Drug Administration (FDA) on its non-clinical program for PF614-MPAR, a 'Next Generation' ...
Loading the latest forecasts...